Search - tctmd.com

Displaying 1 - 20 of 55

Sort: Relevancy | Date

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

News Daily News

Year in Review: STORM-PE, CREST-2, and LIFE-BTK Headline Endovascular News

December 26, 2025

Take Heed of Sex Differences in Peripheral Vascular Disease: AHA

News Daily News

Take Heed of Sex Differences in Peripheral Vascular Disease: AHA

Michael O'Riordan

March 13, 2025

IVC Filter Use Declining, but Retrieval Rates Abysmally Low: SAFE-IVC

News Daily News

IVC Filter Use Declining, but Retrieval Rates Abysmally Low: SAFE-IVC

Michael O'Riordan

November 11, 2024

September 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

September 2024 Dispatch for the CV Team

September 01, 2024

August 2024 Dispatch for the CV Team

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

August 01, 2024

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

News Conference News SCAI 2024

Women, Black Patients Less Likely to Get Advanced PE Therapy, Analysis Shows

May 06, 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

April 16, 2024

Top Endovascular News of 2023

News Daily News

Top Endovascular News of 2023

December 28, 2023

Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel

News Daily News

Medtronic’s Renal Denervation System Fails to Sway FDA Advisory Panel

August 23, 2023

As Renal Denervation Heads to Advisory Review, FDA Sets Out Key Questions

News Daily News

As Renal Denervation Heads to Advisory Review, FDA Sets Out Key Questions

August 18, 2023

BP Reduction With Renal Denervation Still Evident a Decade On

News Daily News

BP Reduction With Renal Denervation Still Evident a Decade On

Michael O'Riordan

January 31, 2023

Reduction in BP Drives Treatment Preference for Hypertensive Patients

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

November 09, 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

News Conference News TCT 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

September 18, 2022

September 2022 News Roundup

News Opinion CV Team Dispatch

September 2022 News Roundup

September 01, 2022

News Industry News

IMPRESSION Randomized Trial: Past the halfway mark and progressing rapidly

January 22, 2022

January 2022 News Roundup

News Opinion CV Team Dispatch

January 2022 News Roundup

January 01, 2022

November 2021 News Roundup

News Opinion CV Team Dispatch

November 2021 News Roundup

November 01, 2021

Renal Denervation a Third Option for Hypertension, European Experts Say

News Daily News

Renal Denervation a Third Option for Hypertension, European Experts Say

September 17, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.